Clinical Trial Update: SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of SENS-401 to prevent cisplatin-induced ototoxicity in adults with cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hearing Loss

Drugs mentioned

• SENS-401

Snippet

Sponsor: Sensorion | Conditions: Hearing Loss Ototoxic | Phase 2 | Status: COMPLETED